Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-09-26

Clinical Trial Update: Inositol to Reduce Retinopathy of Prematurity [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating inositol to reduce retinopathy of prematurity was terminated; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Inositol (inositol)

Snippet

Sponsor: NICHD Neonatal Research Network | Conditions: Retinopathy of Prematurity (ROP) | Phase 3 | Status: TERMINATED | Results posted: 2018-09-26